Introduction
Epithelial ovarian cancer is one of the deadliest malignancies in women (Jemal et al., 2007) . The 5-year survival rate of ovarian cancer has remained relatively unchanged despite extensive efforts to improve the efficacy of treatment (Berek et al., 2010) . Although CA-125 may be a valuable tool in the follow-up of metastasizing ovarian cancer (Bast et al., 1981) , the poor prognosis of this malignancy emphasizes the need to improve disease detection and prognostic stratification.
MicroRNAs (miRNAs) are evolutionarily conserved, non-coding RNA molecules that are usually 21-25 nucleotides in length, which function by binding to the 3 0 -untranslated regions (3 0 -UTRs) of mRNAs, where they repress protein translation or promote mRNA degradation (Bartel, 2004; Griffiths-Jones, 2004) . miRNAs are involved in processes as diverse as apoptosis, the cell cycle, angiogenesis and epithelial-to-mesenchymal transition (EMT) (Gregory et al., 2008; Singh and Settleman, 2010) . In recent years, growing evidence suggests that miRNAs may have oncogenic potential, and aberrant miRNA expressions have been found in many human cancers (Metzler et al., 2004; Takamizawa et al., 2004; Volinia et al., 2006; Yanaihara et al., 2006) . Previous ovarian cancer studies have attempted to identify an aberrant miRNA expression signature by using snap-frozen specimens (Iorio et al., 2007; Lu et al., 2007; Nam et al., 2008; Yang et al., 2008) or formalinfixed, paraffin-embedded (FFPE) tissues (Eitan et al., 2009; Hu et al., 2009) . Iorio et al. (2007) showed that four miRNAs (miR-200a, miR-200b, miR-200c and miR-141) were significantly upregulated in ovarian cancer tissues. Using miRNA microarray analysis, Nam et al. (2008) demonstrated that overexpression of miR-200 in snap-frozen samples was associated with poor patient prognosis. However, a recent study using a PCR-based platform for miRNA expression profiling of FFPE tissues suggested that overexpression of miR200a was associated with a better prognosis in patients with advanced ovarian cancer (Hu et al., 2009) . Although there were obviously distinct differences in assay technologies and tissue sources (Hu et al., 2009) , the exact cause of these discrepancies is unclear.
Dab2 (Disabled homolog-2; gene ID 1601) was first cloned as DOC-2 (differentially expressed in ovarian cancer), which was present in normal ovarian surface epithelial cells but absent in ovarian cancer cell lines (Mok et al., 1994) . Dab2 was considered to be a tumor suppressor because it is absent in 85% of ovarian cancer (Fazili et al., 1999) . More recently, Dab2 was found to be involved in EMT (Prunier and Howe, 2005; Chaudhury et al., 2010) . EMT is a tumor evolutionary process, in which cancer cells acquire invasive and metastatic properties (Singh and Settleman, 2010) .
In this study, we first identified that two miRNAs, miR-187 and miR-200a, were significantly overexpressed in ovarian cancer. Surprisingly, we also found that increased levels of miR-187 and miR-200a in ovarian cancer correlated with the better prognostic group. To solve this paradox, we dissected the mechanistic roles of miR-187 and its target Dab2, and revealed the distinct dual roles of Dab2 in cell proliferation and tumor progression. Table 1 summarizes the significantly differential expression of miRNAs between eight human ovarian cancer cell lines (SKOV3, OVCAR-3, TOV-21G, TOV112D, OV-90, BR, MDAH2774, CAOV3) and two immortalized ovarian surface epithelial cell lines and HOSE), among a panel of 157 miRNAs analyzed. We identified 15 miRNAs that were upregulated in ovarian cancer, and selected the top two miRNAs (miR-187 and miR-200a) for further analyses.
Results

Overexpression of miR-187 and miR-200a in human ovarian cancer cells
Confirmation of high miR-187 and miR-200a expression in human ovarian cancer tissues The expression levels of miR-187 and miR-200a in FFPE ovarian cancer tissues (n ¼ 176) were significantly higher than those seen in benign ovarian tissues (n ¼ 20) (Figure 1a) . Expression of miR-187 was 2.8-fold higher in ovarian cancer tissues than in benign ovarian tissues Table 2 ). In multivariate analyses, lower levels of miR-187 (P ¼ 0.019) and advanced stages (Po0.0001) were the only significant, independent predictors for recurrence-free survival and OS (Table 2) . Survival curve analyses also identified that low levels of miR-187 in ovarian cancer (log ratio p1.3, n ¼ 73) were significantly associated with poorer prognosis than high levels of miR-187 (log ratio41.3, n ¼ 103) (Figure 1b ).
Dab2 was repressed by miR-187 in ovarian cancer cells
Dab2 is one of the genes targeted by miR-187, according to the TargetScan database (Figure 2a) , and microarray analysis of gene expression showed that gene expressions of Dab2 were2.5-fold lower in ovarian cancer cell lines than in immortalized ovarian surface epithelial cells (Po0.003). To confirm that miR-187 directly suppressed Dab2 expression through the target sequences of the 3 0 -UTR of Dab2 mRNA, we constructed a pMir luciferase reporter vector (Luc-Dab2-3 0 -UTR) with the putative 3 0 -UTR target site for miR-187 located downstream from the luciferase gene. Co-transfected miR-187 significantly decreased the reporter activity of LucDab2-3 0 -UTR, but did not affect the reporter activity of mut-Luc-Dab2-3 0 -UTR (Figure 2b ). To support the inhibitory role of miR-187 on Dab2, transfection of anti-miR-187 significantly increased the reporter activity of Luc-Dab2-3 0 -UTR (Figure 2b ). To validate the suppressor role of miR-187 on endogenous Dab2, at both mRNA and protein levels, we compared the effects of miR-187, anti-miR-187 and scrambled control sequences in ovarian cancer cells. Transient overexpression of miR-187 in SKOV3 cells significantly inhibited endogenous Dab2 mRNA, whereas overexpression of anti-miR-187 significantly upregulated Dab2 (Figure 2c) . Similar results were seen in protein regulation; overexpression of miR-187 suppressed endogenous Dab2 protein, whereas antimiR-187 increased it (Figure 2d ). The inhibitory effect of miR-187 on Dab2 protein levels was confirmed in other ovarian cancer cell lines. Transient overexpression of miR-187 significantly suppressed endogenous Dab2 protein levels in TOV112D cells that have a weak endogenous miR-187 expression, whereas transient transfection of anti-miR-187 significantly increased Dab2 proteins in OV90 cells that exhibit strong endogenous miR-187 expression (Supplementary Figure 1) .
Effect of miR-187 on cell proliferation
Ectopic expression of miR-187 in SKOV3 cells suppressed Dab2 (Figure 2 ) and stimulated cell proliferation, as shown by increased bromodeoxyuridine (BrdU) incorporation (Figure 3a) , compatible with the role of Dab2 as a tumor suppressor (Fazili et al., 1999) . On the other hand, expression of anti-miR-187 inhibited BrdU incorporation (Figure 3d ).
Invasiveness of ovarian cancer is regulated by the miR-187-targeted, DAB2-mediated induction of EMT To solve the paradox as to why mildly increased levels of miR-187 in ovarian cancer were surprisingly associated with poorer prognoses for patients (Table 2) , we examined the effect of miR-187 on regulation of cell migration. In transwell migration assays, overexpressed Figure 3c) , and reversed the morphology and vimentin levels in SKOV3 ovarian cancer cells (Supplementary Figure 4b) . Collectively, these results indicated that overexpression of miR-187 inhibited cell migration through inhibition of EMT. Inhibition of EMT by overexpression of miR-187 was mediated by suppression of Dab2, because reconstitution of Dab2 proteins rescued EMT (Figures 4c and d) . Overexpression of Dab2 with the above reconstituting expression vector alone inhibited cell proliferation, stimulated cell migration and promoted EMT (Supplementary Figure 5 ).
Reverse correlations between miR-187 and Dab2 levels in clinical specimens
Reverse correlations between miR-187 levels and Dab2 protein levels, as well as those between miR-187 levels and Dab2 mRNA levels, were validated by immunohistochemical studies of human ovarian cancer FFPE tissues ( Figure 5 ) and real-time quantitative PCR (qPCR) of fresh-frozen samples (Supplementary Figure  6) , respectively. Dab2 protein expression was minimal in ovarian cancer cells with high miR-187 levels (Figure 5a ), whereas ovarian cancer with low miR-187 levels had higher levels of Dab2 protein (Figure 5b ). Benign ovarian tumors were used as positive controls for heavy Dab2 staining (Figure 5c ). The histoscores of the group with low miR-187 expression (log ratio p1.3, n ¼ 73) were significantly higher than the group with higher miR-187 expression (log ratio 41.3, n ¼ 103) (Figure 5d ). In additional fresh-frozen ovarian cancer tissues (n ¼ 20), Dab2 RNA levels were also correlated negatively with miR-187 levels (P ¼ 0.025) (Supplementary Figure 6 ). 
Discussion
This is the first time that miR-187 has been reported to be upregulated in human ovarian cancer (Table 1) , although several miRNAs (miR-200a, miR-200b, miR200c and miR-141) have been reported to be highly expressed in human ovarian cancer (Iorio et al., 2007) . Although aberrant expression of various miRNAs is believed to have an important role in ovarian tumorigenesis (Iorio et al., 2007; Lu et al., 2007; Laios et al., 2008; Nam et al., 2008; Yang et al., 2008; Eitan et al., 2009; Hu et al., 2009) , the relationships between miR-200 levels in the prognoses of ovarian cancer and patients have been conflicting (Nam et al., 2008; Hu et al., 2009) . Higher expressions of miR-200 in ovarian serous carcinoma (n ¼ 20) are significantly correlated with poorer prognosis (Nam et al., 2008) . On the contrary, Hu et al. (2009) reported that patients with advanced disease and higher miR-200a expression had better prognoses than those with lower miR-200a expression (n ¼ 55). Our study boasts the largest number of patients with ovarian cancer ever reported for miRNAs (n ¼ 176), allowing us to investigate paradoxical phenomena such as the high levels of miR-200a and miR-187 expression seen in ovarian cancer as opposed to benign ovarian tissues (Table 1 and Figure 1a) , and how the very high expression levels of these two miRNAs are significantly associated with a better prognosis (Table 2 and Supplementary Table 2) .
EMT is a critical step in tumor progression (Thiery, 2002) . miR-200-family members are fundamental regulators of EMT (Gregory et al., 2008; Peter, 2009) , whereas miR-30 (Braun et al., 2010) and miR-661 (Vetter et al., 2010) Figure 1b . The histoscores of the low-miR-187-expression group (log ratio p1.3, n ¼ 73) were significantly higher than those of the group with higher miR-187 expression (log ratio 41.3, n ¼ 103). Figure 6 The dual roles played by miR-187 in ovarian cancer cells through fine tuning of Dab2 protein levels were independent of miR-200a. In miR-200a-knockdown SKOV3 cancer cells, overexpression of miR-187 inhibited Dab2 protein levels, increased cell proliferation (a) and inhibited EMT, which was shown by increased E-cadherin protein and decreased vimentin levels (c). In the same miR-200a-knockdown cancer cells, transfection with anti-miR-187 exerted the opposite effects of miR-187 (b, d). Actin was used to confirm equal protein inputs in all lanes. The quantitative results of immunoblots are summarized in Supplementary Figure 7 . The data shown as mean ± s.e. are calculated from three independent experiments. *Po0.05 when compared with controls. (e) Expression of miR-187 is generally higher in ovarian cancer than in benign ovarian epithelia. Through inhibition of Dab2, which acts as a tumor suppressor, high levels of miR-187 promote cell proliferation (upper panel). During tumor cell evolution, some ovarian cancers continue upregulating miR-187 levels (shown here by the miR-187 4log ratio 1.3 group), resulting in very low protein levels of Dab2, low EMT and a better prognosis. On the other hand, some ovarian cancers stop upregulating miR-187 levels (shown here by the miR-187 plog ratio 1.3 group) and thus maintain low but functional levels of Dab2 that is required for EMT, resulting in aggressive tumor progression and a poorer prognosis (lower panel).
miRNAs regulate oncogenes and tumor-suppressor genes in tumorigenesis A Chao et al increases E-cadherin and inhibits cancer progression by suppressing EMT (Gregory et al., 2008) . In agreement with those findings, we also found that very high expression of miR-200a is associated with a better prognosis (Supplementary Table 2 ), presumably through suppression of EMT. For the first time, very high levels of miR-187 in ovarian cancer patients are found to be associated with better survival (Table 2 and Figure 1b) , possibly through regulation of Dab2-mediated EMT.
To support that miR-187 exerts dual Dab2-mediated roles in regulating the development of ovarian cancer, we first confirmed that miR-187 directly targets Dab2 (Figure 2 ) and stimulates the proliferation of ovarian cancer cells (Figure 3) . Overexpression of miR-187 inhibits Dab2, vimentin, phospho-FAK and cell migration, and such inhibition can be rescued by re-expression of a T7-tagged Dab2 that cannot be suppressed by miR-187 (Figure 4) . These results collectively confirm that miR-187 regulates EMT through Dab2.
miR-187 is located in chromosome 18q12.2, and its target motif is a 7mer8-m8 seed-matched site of position 77-83 of the Dab2 3 0 -UTR (Targetscan4.0, 2007). In clinical ovarian cancer tissues, reverse correlations between Dab2 immunoreactivities and miR-187 levels ( Figure 5 ) also support the hypothesis that miR-187 targets Dab2. Dab2 is downregulated in several cancers and is frequently undetectable in breast and ovarian cancer (Mok et al., 1998; Fazili et al., 1999) . In Dab2-knockout mice, Dab2-haplodeficient (dab2 þ /À ) female mice frequently develop widespread uterine hyperplasia and ovarian pre-cancer morphological features (Yang et al., 2006) . Interestingly, Dab2 is also crucial for transforming growth factor-b-induced EMT, where downregulation of Dab2 prevents EMT and promotes apoptosis in murine mammary gland epithelial cells (Prunier and Howe, 2005) . Dab2 may be a tumor suppressor, but in late cancer stages it is also functionally important for tumorigenesis by promotion of EMTmediated metastasis (Prunier and Howe, 2005; Chaudhury et al., 2010) . During the progression of human squamous cell carcinoma, downregulation of Dab2 switches transforming growth factor-b from tumorsuppressor to tumor-promoting functions (Hannigan et al., 2010) . Clearly, Dab2 appears to have a dual role in tumor progression.
In conclusion, our study results demonstrate distinctly dual roles of miR-187, through Dab2 targeting, in cell proliferation and tumor progression (Figure 6 ). In the initial steps of tumorigenesis, upregulated miR-187 suppresses Dab2, promoting cell proliferation. During the microevolution of cancer cells, some cells further upregulate miR-187 and inhibit Dab2-dependent EMT, which is associated with tumor invasiveness. The overshooting mechanism may account for the paradoxical observation that ovarian cancers with high miR-187 levels were associated with better survival (Figure 1b and Table 2 ). On the other hand, in cancer cells that maintain the increased miR-187 levels low enough, the functional Dab2 promotes EMT, tumor progression and metastases, which are associated with poorer prognoses of cancer patients (Figure 6e ). Of note, the above effects of miR-187 are independent of miR-200a (Figure 6 ).
Materials and methods
Cell culture
Seven ovarian cancer cell lines (SKOV3, OVCAR-3, TOV-21G, TOV112D, OV-90, MDAH2774 and CAOV3) were obtained from the American Type Culture Collection (Manassas, VA, USA). The ovarian cancer cell line BR was established as described previously (Wang et al., 1998 ). An immortalized human ovarian surface epithelial cell line (IOSE-80PC), originally from Dr Andrew K Godwin (Fox Chase Cancer Center, Philadelphia, PA, USA) (Yang et al., 2004) , was provided by Dr Peter CK Leung (British Columbia Children's and Women's Hospital, Vancouver, BC, Canada) (Choi et al., 2006) . Another human ovarian surface epithelial (HOSE) cell line was provided by Dr SW Tsao (University of Hong Kong, Hong Kong) (Chung et al., 2005) . Cells were cultured in 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 U/ml) and Dulbecco's modified Eagle's medium (DMEM)/F12 media at 37 1C in a 5% CO 2 atmosphere.
Patients and ovarian tumor tissues
Tissue samples (FFPE tumor blocks) were available from 176 patients with ovarian cancer. Clinical information of the patients was archived in the databank of the Division of Gynecologic Oncology, Chang Gung Memorial Hospital, Taiwan. Benign epithelial ovarian tumor tissues were used as controls. Additional 20 fresh frozen samples of ovarian cancer were included for confirmation of the correlation between miR and its targeted gene (Supplementary Table 3 ). This translational study was approved by the Institutional Review Board of the Chang Gung Memorial Hospital (IRB No. 95-1364B and 97-1444C).
RNA extraction RNA was extracted from FFPE tissues by using the Recover All Total Nucleic Acid Isolation system (Ambion, Austin, TX, USA) as described previously (Chao et al., 2010) . In brief, FFPE tissues were cut into 2-3 sections of 10-mm thickness. Tumor tissues were carefully macrodissected from section slides using a scalpel and transferred into a sterile 1.5-ml centrifuge tube. The paraffin was removed by using 100% xylene at 50 1C for 3 min. After centrifugation, xylene was discarded and the pellet was washed with 100% ethanol and air-dried. The pellet was protease-digested for 3 h at 50 1C and RNA was purified through filter cartridges. Total RNA was extracted from cell lines or fresh frozen tissues using TRIZOL (Invitrogen, Carlsbad, CA, USA).
Real-time qPCR miRNA assay of cell lines and ovarian tissues miRNA profiling of human ovarian cancer cell lines and immortalized human ovarian surface epithelial cell lines was performed by using the TaqMan MicroRNA Assays Human Panel Early Access kit containing 157 mature miRNAs (Applied Biosystems, Foster City, CA, USA). The expression levels of miR-187 and miR-200a in both cell lines and FFPE tissues were analyzed by using the TaqMan MicroRNA Assay (#ABM000500; Applied Biosystems). The expression levels of hsa-miR-16 (TaqMan MicroRNA Assay, #ABM000008) were used as internal control. The expression levels of DAB2 in cell lines were quantified by using the SYBR green assay (Applied miRNAs regulate oncogenes and tumor-suppressor genes in tumorigenesis A Chao et al Biosystems). The expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as internal control. The primer sequences for DAB2 were as follows: forward, 5 0 -GGGCATTTGGTTACGTGTG-3 0 and reverse, 5 0 -CTTTGC TGGCTTCCTCTATC-3 0 . The primer sequences for ZEB1 were as follows: forward, 5 0 -AAGAATTCACAGTGGAGAG AAGCCA-3 0 and reverse, 5 0 -CGTTTCTTGCAGTTTGGGC ATT-3 0 . For amplification of GAPDH, the primers used were as follows: forward, 5 0 -GGTATCGTGGAAGGACTCATG AC-3 0 and reverse, 5 0 -ATGCCAGTGAGCTTCCCGT-3 0 . The amplification conditions were as follows: initial denaturation for 10 min at 95 1C, followed by 45 cycles of 95 1C for 15 s and 60 1C for 1 min. The reactions were performed by using the ABI PRISM 7900 HT instrument (Applied Biosystems). A mean cycle of threshold (C t ) value for each duplicate measurement was calculated.
Plasmids
The expression vector of the selected miR-187 and the scrambled control were constructed by annealing the following oligonucleotides: miR-187 forward (F): 5 0 -AGCTTGGTCGG GCTCACCATGACACAGTGTGAGACCTCGGGCTACAA CACAGGACCCGGGCGCTGCTCTGACCCCTCGTGTCT TGTGTTGCAGCCGGAGGGACGCAGGUCCGCAA-3 0 and miR-187 reverse (R): 5 0 -TGCGGACCTGCGTCCCTCCGGC TGCAACACAAGACACGAGGGGTCAGAGCAGCGCCC GGGTCCTGTGTTGTAGCCCGAGGTCTCACACTGTGT CATGGTGAGCCCGACC-3 0 ; scrambled forward: 5 0 -AGCT TGTGTAACACGTCTATACGCCCAGTGTAACACGTCT ATACGCCCAGAT-3 0 and scrambled reverse: 5 0 -ATCTGGG CGTATAGACGTGTTACACTGGGCGTATAGACGTGT TACACA-3 0 , in DNA annealing buffer (30 mM HEPES (pH 7.4), 100 mM potassium acetate and 2 mM magnesium acetate). The mixture was heated at 95 1C for 5 min and then incubated at 37 1C for 1 h. The inserts were ligated into pcDNA3.1 (Invitrogen) treated with HindIII (miR-187) and HindIII/ EcoRV (scrambled control), respectively. The pMir luciferase reporter vectors contained the 3 0 -UTR of the DAB2 gene (Luc-DAB2-3 0 -UTR) that were amplified from IOSE cDNA using the DAB2-3 0 -UTR forward primer 5 0 -CAAAGCTGATAGC CAGACACGTTC-3 0 and the DAB2-3 0 -UTR reverse primer 5 0 -CCTGAGCATTAAGGGTCAAGAG-3 0 . The forward primer for mutant Luc-Dab2-3 0 -UTR was 5 0 -CAAAGCTGA TAGCCAGACAATTTC-3 0 . The pMir luciferase reporter vectors contained the 3 0 -UTR of the ZEB1 gene (Luc-ZEB1-3 0 -UTR) by using the ZEB1-3 0 -UTR forward primer 5 0 -CCA CTGACTCTGTCAGAGAAACTG-3 0 and the ZEB1-3 0 -UTR reverse primer 5 0 -GCTTCCCTGAAATGACCTGA-3 0 . The PCR conditions were as follows: 95 1C for 5 min, followed by 40 cycles of 95 1C for 1 min, 55 1C for 1 min and 72 1C for 90 sec, and a final extension step at 72 1C for 10 min. After confirming the sequence, the PCR products were digested with HindIII and ligated into the HindIII/CIP-treated pMirreporter vector (Ambion). The correct assembly of the constructs was confirmed by DNA sequencing. The Dab2 expression plasmid was a gift from Dr Ching-Ping Tseng (Department of Medical Biotechnology and Laboratory Science, Chang Gung University).
DNA transfection
For miR-187 overexpression experiments, pcDNA-miR-187 or pcDNA-scrambled were transfected into SKOV3 cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Transient transfection was performed 48-72 h prior to cell harvest, unless otherwise specified. For anti-miR-187 experiments, the anti-miR-187 or anti-scrambled duplexes (Exiqon, Vedbaek, Denmark) were transfected into SKOV3 cells at a final concentration of 5 nM using the Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. Transient transfection was performed 72 h prior to cell harvest, unless otherwise specified.
The LNA-anti-miR-187 sequence was 5 0 -CCGGCTGCAA CACAAGACACGA-3 0 ; the LNA-anti-miR-200a sequence was 5 0 -ACATCGTTACCAGACAGTGTTA-3 0 and the LNAanti-scramble sequence was 5 0 -GTGTAACACGTCTATACG CCCA-3 0 .
Luciferase reporter assay Cells were transfected with DNA and the Lipofectamine 2000 reagent in OPTI-MEM medium. Lipofectamine 2000 and DNA were mixed gently and incubated at room temperature for 30 min to allow the formation of DNA-Lipofectamine 2000 complexes. The cells were placed in serum-free medium and then overlaid with DNA-liposome complexes. The cells were lysed with 1 Â Reporter lysis buffer (Promega, Madison, WI, USA) and luciferase activity was measured by using the Dual-Glo Luciferase assay system (Promega) according to the manufacturer's protocol. In each sample, luciferase activity was normalized to Renilla luciferase activity to minimize inherent variation in transfection efficiency.
Western blot analysis Cells were harvested, washed twice in phosphate-buffered saline (PBS) and lysed in ice-cold radio-immunoprecipitation assay lysis buffer (1% Triton X-100, 1% NP-40, 0.1% sodium dodecyl sulfate, 0.5% DOC, 20 mM Tris-hydroxymethylaminomethane (Tris-HCl, pH 7.4), 150 mM NaCl, protease inhibitor cocktail (Sigma, St Louis, MO, USA) and phosphatase inhibitor (Sigma)) for 30 min. The lysates were mixed with 4 Â sample buffer, boiled and fractionated by sodium dodecyl sulfate-PAGE. Following electrophoretic separation on 8% sodium dodecyl sulfate-PAGE gel, the proteins on the gels were transferred to nitrocellulose membranes (Amersham Pharmacia Biotech, Uppsala, Sweden). The blots were probed with an antibody specific to DAB2 (Becton Dickinson, Franklin Lakes, NJ, USA), phospho-397 FAK (Abcam, Cambridge, MA, USA), FAK (Cell Signaling Technology, Danvers, MA, USA), E-cadherin (Epitomics, Burlingame, CA, USA), vimentin (Epitomics) and appropriate secondary antibodies. The labeled bands were subsequently detected by enhanced chemiluminescence (ECL; Millipore, Bedford, MA, USA). For each sample, band intensities were normalized to b-actin (Sigma) (Chao et al., 2010) .
BrdU incorporation assay
To study the effect of miR-187 on proliferation ability, SKOV3 cells that overexpressed either miR-187 or anti-miR-187 were seeded in a complete culture medium at a density of 10 4 cells per well in a 96-well plate for 12 h. After addition of BrdU, the cells were grown for another 12 h. DNA synthesis was assayed by ELISA for BrdU incorporation (Roche Applied Science, Indianapolis, IN, USA) (Chao et al., 2010) .
Cell migration assays SKOV3 cells (2 Â 10 4 /well) overexpressing either miR-187 or anti-miR-187 were plated in DMEM, 10% FBS in the upper chamber of 8-mm pore (24-well) transwells (Corning and Transwell, NY, USA). The lower chamber was filled with 800 ml of DMEM/F12 media containing 0.5 mg/ml fibronection (Sigma). After a 24-h incubation period, the cells that had miRNAs regulate oncogenes and tumor-suppressor genes in tumorigenesis A Chao et al migrated through the pores and reattached to the lower chamber were fixed with methanol and stained with Giemsa (Sigma) and imaged, and the number of migrating cells was counted. Five random fields were analyzed for each chamber. The assays were conducted in three independent experiments.
Wound-closure assays
To study the effect of miR-187 on cell migration, SKOV3 cells that overexpressed either miR-187 or anti-miR-187 were analyzed by using the Culture-Inserts (Ibidi, Germany). The Culture-Inserts were transferred to 3.5-cm dishes and cells were seeded in a complete culture medium at a density of 4200/ well in the Culture-Inserts. After 12 h of culture, the CultureInserts were removed to create cell-free gaps. The medium was replaced with fresh serum-free medium. Phase-contrast images of the gaps were captured at 0 h (control), and 16 h (miR-187) or 24 h (anti-miR-187) of incubation using an inverted microscope (magnification, Â 10). Wound-closure analyses were quantified by using the WimScratch software (Wimasis, Munich, Germany). The percentage of migrated cells was calculated by subtracting the cell coverage % of the remaining wound areas from the original % at the beginning of experiment. The result was then normalized by the control group.
Immunohistochemical study FFPE tissue slices (ovarian cancer and normal ovary, each 4-mm thick) were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol. The sections were immunostained with an anti-DAB2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:75 dilution by using the ES automated immunohistochemical stainer (Ventana Medical Systems, Tucson, AZ, USA), as described previously (Chao et al., 2006) . The overall immunohistochemical score (histoscore) in this study was the percentage of positive cells multiplied by its staining intensity (0 ¼ negative, 1 ¼ weak, 2 ¼ moderate, 3 ¼ strong), and ranged from 0 to 300 (100% multiplied by 3) (Liao et al., 2011) .
Confocal immunofluorescence microscopy SKOV3 cells (2 Â 10 5 /well in six-well plates) were grown on sterilized coverslips overnight and the cells were co-transfected with either miR-187 and pCR3.1-EGFP or anti-miR-187 and pCR3.1-EGFP by using Lipofectamine 2000 (Invitrogen). After 48 h, the cells were fixed with 3.7% formaldehyde for 10 min prior to permeabilization with Triton X-100 (0.2% in PBS, for 5 min) and incubated in blocking buffer (5% normal goat serum in PBS) to reduce non-specific binding for 1 h at room temperature. The cells were incubated with a polyclonal anti-rabbit vimentin antibody (Epitomics; 1:50) for 1 h. After washing, the cells were incubated with an Alexa Fluor-546 anti-rabbit IgG (Invitrogen; 1:200) for 1 h prior to washing and mounting. The slides were mounted with the Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA) and analyzed by using the Leica TCS SP2 laser scanning confocal system (Leica Inc, Germany).
Microarray analysis and target prediction of miRNA-overexpressing ovarian cancer cell lines Parallel analyses of gene expression profiles in ovarian cancer cell lines overexpressing miR-187 or cells expressing vector alone were performed by using the Human Genome U133A array (Affymetrix, Santa Clara, CA, USA), which contains the oligonucleotide probe set for 22 218 human genes (Tsai et al., 2007; Lee et al., 2009 ). We used TargetScan 4.0 (http:// www.targetscan.org/) to identify potential target sites of differentially expressed miRNAs.
Bioinformatics and data analysis
The signal intensities of the miRNA data in ovarian cancer cell lines and immortalized human ovarian surface epithelia cell lines were normalized by the quantile normalization method combined with a permutation test by using BioInformatics Toolbox Software 3.1 (R2008a) in MATLAB. SAM (Significance Analysis of Microarrays) by using a software from the Stanford University labs (Tusher et al., 2001 ) was performed to investigate the differential expression of miRNAs.
In transfection experiments, Student's t-tests were used to evaluate the effects of miRNA or anti-miRNA on mRNA and targeted protein levels, which were analyzed by qPCR and western blot analyses, respectively. Two-tailed P-values o0.05 were considered significant.
The main outcome measures were recurrence-free survival and OS. Recurrence-free survival was defined as the time interval between the date of primary surgery and the date of the first recurrence. OS was calculated as the time period from the date of primary surgery to the date of death. A Cox proportional hazards regression model was used for the analysis of prognostic factors. The results were expressed as hazard ratios with 95% confidence intervals. To define the independent contribution of each risk factor (clinical variables and miRNA expression), we performed a multivariable Cox proportional hazards analysis. Survival curves were calculated by the Kaplan-Meier method and compared for statistical significance by using the log-rank test. Grouping cut-off points were selected as the value corresponding to the highest accuracy (sum of maximum sensitivity and specificity) of the receiver operating characteristics curve analysis. Patients were grouped into the low-miR-187 group (log ratio p1.3, n ¼ 73) and the high-miR-187 group (log ratio 41.3, n ¼ 103). Statistical analyses of the clinical endpoints were performed by using the SPSS statistical software, version 17.0 (SPSS Inc, Chicago, IL, USA). Two-tailed P-values o0.05 were considered significant.
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